Submission of unaudited Financial results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.9 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hindustan Agrigenetics Limited reported standalone unaudited results for Q2 FY26 and H1 FY26 (ended Sept 30, 2025). Revenue from operations was nil in Q2 FY26 (same as Q2 FY25), with only ₹4.33 lac for H1 FY26. Total revenue (including other income) stood at ₹25.41 lac for Q2 and ₹80.89 lac for H1, but was inflated by investment value changes (₹29.61 lac in Q2 FY25, ₹0.79 lac in Q2 FY26) and interest income. PAT was ₹18.85 lac in Q2 FY26 versus ₹17.79 lac in Q2 FY25, and ₹59.05 lac for H1 FY26 versus ₹22.17 lac for H1 FY25 (a ~166% jump). H1 EPS came in at ₹1.34 versus ₹0.50 last year. The balance sheet shows a cash and investments-heavy book (₹5.38 crore cash, ₹3.96 crore investments) with negligible liabilities, and the company extended a ₹2.5 crore loan to Vedavaag Systems Ltd during the period. The auditor issued an unqualified limited review report.
The company has effectively no operating business — all reported profit comes from investment gains and interest income, making earnings non-recurring and dependent on market movements. Investors should treat this as an investment-holding shell rather than an operating company, and the headline PAT growth should not be read as a business turnaround.